Why they built it
Surgeon Albert Huang struggled to identify the ureter during minimally invasive surgery, a step that could require careful dissection or help from a urologist. He explored whether electrical stimulation could make the ureter visibly contract even when obscured by tissue. Allotrope built StimSite as a hand-held system to help general and OBGYN surgeons identify ureters in robotic and non-robotic laparoscopic procedures.
How it ended
Allotrope did not close as a failure; Northgate Technologies announced it had completed the acquisition of Allotrope on April 4, 2023. Northgate described StimSite as a complement to its insufflation and surgical smoke-removal products. The announcement did not disclose the purchase price or establish that the business was failing.
What went wrong
Most important first.
- 1
Became part of larger surgical portfolio Other
Northgate announced completion of the acquisition on April 4, 2023 and positioned StimSite alongside its existing insufflation and smoke-removal products.
What could be different today
- StimSite has an FDA substantially equivalent decision under K200886 dated November 10, 2020, so a rebuild would face a cleared predicate device.
- StimSite was reported to have Safer Technologies Program designation in November 2022, which a new product would need to account for.
- StimSite is owned by Northgate after the April 4, 2023 acquisition as a complement to its insufflation and smoke-removal products, so a rebuild would compete with an established surgical-device portfolio.